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Abstract
DBD* is a novel gene encoding an 89 amino acid peptide
that is constitutively lethal to leukemic cells. DBD* was
derived from the DNA binding domain of the human
glucocorticoid receptor by a frameshift that replaces the
final 21 C-terminal amino acids of the domain. Previous
studies suggested that DBD* no longer acted as the
natural DNA binding domain. To confirm and extend
these results, we mutated DBD* in 29 single amino acid
positions, critical for the function in the native domain
or of possible functional significance in the novel 21
amino acid C- terminal sequence. Steroid- resistant
leukemic ICR-27-4 cells were transiently transfected
by electroporation with each of the 29 mutants. Cell kill
was evaluated by trypan blue dye exclusion, a WST-1
tetrazolium-based assay for cell respiration, propidium
iodide exclusion, and Hoechst 33258 staining of chro-
matin. Eleven of the 29 point mutants increased, where-
as four decreased antileukemic activity. The remainder
had no effect on activity. The nonconcordances be-
tween these effects and native DNA binding domain
function strongly suggest that the lethality of DBD* is
distinct from that of the glucocorticoid receptor. Trans-
fections of fragments of DBD* showed that optimal
activity localized to the sequence for its C-terminal 32
amino acids.
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Introduction
DBD* is herein defined as the gene encoding the native
sequence for amino acids (a.a. ) 398 to 465 of the human
glucocorticoid receptor (hGR), plus a novel 21 a.a. C-
terminal peptide, for a total of 89 a.a. The frameshift that
mutated the hGR rendered it transcriptionally inactive and
removed its ligand binding domain [1]. That mutation
resulted in a gene encoding hGR a.a. 1 to 465 followed by
the novel 21 a.a. and has been designated as 1-465*. We
have shown that transfection of expression plasmids
containing 1-465* or DBD* cause extensive apoptotic death
of several lines of malignant B and T cells but have no effect
on two myeloid cell lines [2–4]. Because DBD* showed
equal potency to 1-465*, we focused our attention on the
smaller gene. It lacks the nuclear localization signal, steroid-
binding domain, and the AF-1/ tau 1, tau 2 and AF-2
transcription-activating domains of the natural hGR [5,6].
Database searches of the DBD* predicted protein (pDBD*)
indicated that the C-terminal 21 a.a. sequence is unique.
The complete mechanism of action through which DBD*
kills some malignant cells is unknown. We have established,
however, that the protein encoded by DBD* or 1-465* is
made before the onset of death and that transiently blocking
protein synthesis delays the onset of death until the synthetic
block is lifted (Refs. [4,7 ]; unpublished observations).
Transfection studies with 1-465* showed that it has no
capacity for inducing genes driven by a classic glucocorticoid
response element (GRE) [1,8 ]. Further, this mutant does not
interfere with the inductive capacity of natural hGR, nor did it
nonspecifically block (squelch) transcription [8]. pDBD* or
the larger protein from 1-465* containing DBD* does not bind
a GRE or induce a GRE-driven reporter gene in vitro, and the
mutant proteins do not interfere with GRE-specific, hGR-
dependent gene induction in a cell - free system [8]. DBD* or
DBD* containing genes cause apoptotic cell death, appa-
rently by a sequence of events leading to activation of the
caspase 3 system [4]. When tagged with the jellyfish green
fluorescence protein, chimeric DBD* containing peptides
localize primarily in the cytoplasm of CEM cells [4 ].
The lethal activity of DBD* on lymphoid malignancies, its
lack of effect in the classic hGR pathway, and its unique
sequence combined to suggest that it may provide the basis
for novel therapies against certain malignancies. To confirm
that DBD* was not acting in the form of the native hGR DNA
binding domain, we mutagenized 29 selected codons of
DBD*. These were chosen because of their established
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relevance to functions of the native domain or for their
presence in the novel 21 a.a. C- terminus. We also divided
DBD* into smaller fragments and compared these for lethal
activity. Our results show 1) that it is quite unlikely that DBD*
acts as a result of a structure resembling that of the native
hGR DNA binding domain, 2) that the novel C- terminal
sequence is very important for the lethal function, and 3) that
the 32 a.a. C- terminal fragment has optimal potency.
Materials and Methods
Cells and Cell Culture
The CCRF-CEM cell line was established from the
peripheral blood of a child with acute lymphoblastic leukemia
[9]. CEM-C7 is a glucocorticoid-sensitive clone obtained
from this line [10]. By high-dose dexamethasone selection
after mutagenesis, the glucocorticoid- resistant clone ICR-
27 that contains only an inactive mutant hGR allele was
isolated from CEM-C7 cells [11,12]. To assure that the cells
for this study possessed the original characteristics, ICR-27
cells were recently recloned, and the highly glucocorticoid-
resistant subclone ICR-27-4 (1 M dexamethasone for
4 days) was used. ICR-27-4 cells were cultured at 378C in
RPMI 1640 medium, pH 7.4 (Cellgro from Media Tech,
Herndon, VA), with 5% heat- inactivated fetal bovine serum
(FBS, Atlanta Biologicals, Norcross, GA) in a humidified
atmosphere of 95% air, 5% CO2. Cells were maintained in
early to mid- logarithmic growth, and their viability was
determined by exclusion of trypan blue dye for at least
15 minutes (Sigma-Aldrich, St. Louis, MO) [13].
Single Site Mutations
The protocol for the transformer site-directed muta-
genesis kit from Clontech (Mountain View, CA) was
followed. To simplify the mutagenic reactions, the DBD*
sequence was cloned into pUC19 plasmid from pHook/
DBD*, using KpnI and BamHI restriction sites so that the
control primer from the Clonetech kit 50 GAGTGCAC-
CATGGGCGGRGTGAAAT 30 could be used to introduce
site-specific mutations. The mutants were confirmed by
DNA sequencing and cloned into a pHook2 expression
vector ( Invitrogen, Carlsbad, CA).
DBD* Fragment Construction
Four DBD* fragments were created to test the relative
potency of each in comparison to the holotype DBD*. PCR
primers were designed to amplify the four individual frag-
ments from a purified 1-465* starting template. To simplify
cloning into the pHook2 expression vector system, the 50PCR
primers included a restriction site for XbaI and the
30 oligonucleotides contained a site specific for BamHI.
Fragment 1 (a.a. 398–456) consisted of the region from the
N-terminal end of DBD* to the base of the putative second
zinc finger, whereas fragments 3 (a.a. 425–486), 2 (a.a.
439–486), and 4 (a.a. 455–486) were progressively smaller
portions of the C-terminal end of DBD* protein. DNA se-
quencing was performed to validate all PCR amplifications.
Transient Transfection of ICR-27-4 Cells by Electroporation
The transient transfection of the ICR-27-4 cells followed
the protocol of Thulasi et al. with slight modifications [14].
Cells were washed once at 48C with PD buffer (phosphate-
buffered isotonic saline, PBS, pH 7.4, devoid of Ca2+ and
Mg2+ ) and resuspended to 1107 cells /ml in the cold PD
buffer. Fifteen micrograms of each plasmid DNAwere diluted
into 0.35 ml of cold PD buffer and mixed with an equal
volume of cells. After 5 minutes in the PD buffer in an ice
bath, the cells were pulsed for 13 to 14 milliseconds
(average=13.7±0.2) with 300 V and 500 F using a Gene
Pulser with 0.4 cm electroporation cuvettes (Bio-Rad
Laboratories, Hercules, CA). Extensive preliminary experi-
ments had shown that with these electroporation conditions
both DBD* and 1-465* reduced the number of viable ICR-
27-4 cells by about 25% at 24 to 48 hours after transfection
[3,4,8]. These conditions allowed survival of about 95% of
cells transfected with the vector plasmid DNA and produced
about 45% electroporation efficiency [3]. More intense
electroporation conditions gave higher efficiency, but caused
much greater nonspecific cell death [7 ]. Electroporation
without DNA gave equivalent results. The cuvettes were then
reincubated in an ice bath for 10 minutes, after which the
cells were transferred to 7 ml of RPMI 1640 with 5% FBS and
placed in the 378C incubator. Three hours later, the cells
were counted without trypan blue dye to establish accurate
initial total cell concentrations. After 24 and 48 hours’
incubation, counts with trypan blue dye present were used
to enumerate viable cells. The response was expressed as
percentage of cells killed relative to controls:
1 Viable cells with pHook=DBD
 or mutant
Viable cells with pHook vector
 
100%
Cell Viability Determined by WST-1 Reagent
This colorimetric microplate assay based on the cleavage
of the slightly yellow–red tetrazolium salt WST-1 to a soluble
dark red–blue formazan salt by mitochondrial dehydro-
genases in viable cells was performed, following the
instructions of the manufacturer (Roche Diagnostics /Boeh-
ringer Mannheim, Indianapolis, IN). Four 200-l aliquots of
cell cultures that had been subjected to each treatment were
removed at 24 and 48 hours and placed in a 96-well plate;
20 l of freshly prepared and filtered WST-1 reagent was
added, mixed with the suspension, and the cells were
allowed to incubate overnight at 378C in the dark. The
absorbance of the stable formazan product was measured at
450 nm, with a background reference wavelength of 595 nm.
Apoptosis Determined by Propidium Iodide Exclusion and
Hoechst 33258 Staining
The propidium iodide (PI) exclusion assay for viability
was carried out as described [15]. Twenty- four hours after
electroporation 1 ml of cells was transferred from their tissue
culture flask into 1275-mm tubes. Immediately after adding
PI to a final concentration of 10 g/ml, the samples of cells
were analyzed by flow cytometry for cell size ( forward
scatter, FSC), cell density (side scatter, SSC), and live/
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dead (negative /positive PI ) on a FACScan instrument
(Becton Dickinson, Bedford, MA), with excitation at 488
nm and emission followed at 530 nm. The percentage of
viable cells was determined by analyzing forward and side
scatter combined with negative or positive PI staining. To a
second aliquot of cells, Hoechst 33258 (Sigma-Aldrich) was
added to a final concentration of 25 g/ml. After 15 minutes,
cells were washed once with PD buffer and deposited by
centrifugation (600 rpm, 2 minutes) on microscope slides
precoated with poly-L- lysine (Cytospin 3 centrifuge, Shan-
don-Lipshaw, Pittsburgh, PA). The slides were preserved
with Crystal Mount (Biomeda, Foster City, CA) and stored in
the dark at 48C. Images of the stained cells were captured by
photomicrography with a Nikon FDX-35 camera mounted on
a Nikon Eclipse E600microscope (Melville, NY). Illumination
was with white polarized light, with an excitation filter of 360/
340 nm; a barrier filter of 460/50 nm, and a 400 dichronic
mirror for the Hoechst -stained cells.
Results and Discussion
The 89 a.a. sequence of pDBD* is shown (using the
numbering for full - length hGR) with each a.a. to be mutated
in bold and highlighted (Scheme 1).
We constructed four fragments of DBD* as shown above
to identify regions important for lethal activity. Fragment 1
represented all normal hGR sequence. Fragments 2, 3, and
4 each contained the novel C- terminal peptide, plus varying
amounts of preceding sequence. The single a.a. alterations
were selected to produce a change in: 1) helicity (by
changing to a helix -breaking proline); 2) hydrophobicity or
hydrophilicity; 3) electrical charge; 4) an a.a. conserved
within the steroid hormone receptor family; 5) loss of
potential zinc coordination; or 6) change in distance between
‘‘zinc finger’’ sequences. The a.a. chosen for mutation were
selected based on their known functions in the normal hGR
DBD (protein–DNA interaction, transactivation/ repression,
receptor dimerization and protein–protein interaction) or for
their contribution to potential secondary structure in DBD*
[16]. Transfection of fragments 1 to 4 showed that fragment
1 was much less potent than fragments 2 to 4. Figure 1A
shows the growth curves of ICR-27-4 cells after transfection
with pHook-2 vector, DBD*, and the four DBD* fragments.
Fragment 1 (a.a. 398–456) represented 75% of DBD* from
the N-terminal end but at best had only a transient effect.
The C- terminal fragments 2 to 4 that all contained the 21
novel a.a. showed a sustained effect. Fragment 2 (a.a. 439–
486) encompassed about 50% of DBD* and exhibited more
cell kill (39±13% reduction in cell numbers) than DBD*,
as did the smallest C- terminal fragment, fragment 4 (a.a.
455–486, 43±8%). Fragment 3 (a.a. 425–486), the longest
C- terminal fragment, had activity similar to DBD* (27±5%).
Thus, fragment 4, encoding only a 32 a.a. protein, exhibited
the greatest lethality toward ICR-27-4 cells, particularly
notable at 48 hours.
We subsequently tested constructs containing shorter
portions of fragment 4 to determine the minimum fragment
retaining maximum lethality. Fragment 6 (a.a. 455–467)
represented the N-terminal half of fragment 4 and the C-
terminal fragment 7 (a.a. 468–486) contained only the
unique a.a. Fragment 7 was further subdivided into frag-
ments 7a (a.a. 468–483) and 7b (a.a. 468–480). Figure 1B
shows the results of transfecting these fragment into ICR-
27-4 cells. Whereas fragment 2, 4, and 7 all produced cell kill
greater than DBD*, the response to fragment 4 was more
consistent, with t test paired analyses yielding P=.0003 for
fragment 4, .03 for fragment 7, and .08 for fragment 2. These
[- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -Fragment 1- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ]
MKPDVSSPPSSSSTATTGPPPKLCLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIAIKFEEKTAQHAAIENVFRLE
398 423 439 450 460 480
[- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -Fragment 2- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ]
[- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -Fragment 3- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ]
[- - - - - - - - - - - - - - -Fragment 4- - - - - - - - - - - - - - - - - - - - - - ]
Scheme 1.
Figure 1. Lethal effects of DBD* and fragments thereof after electroporation of
ICR -27 -4 cells. ICR -27 -4 cells were transiently transfected with 15 g of
each plasmid DNA with plasmid pHook2 as the control. At 3 hours the cultures
were counted without trypan blue dye and normalized to 1105 cells /ml. At
24 and 48 hours after electroporation viable cell numbers were determined by
trypan blue dye exclusion with standard deviation. (A ) shows the growth curve
of cells after transfection, n=15 to 24 separate electroporations for each
fragment and 45 for DBD*. (B ) shows the cell kill response of DBD* and its
smaller fragments with the a.a. sequence given inside each bar; n=6 to
21 separate electroporations for each fragment and 57 for DBD* with standard
deviation.
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data, plus the fact that deletion of the 21 C- terminal a.a.
( fragment 6) caused loss of lethal activity, led us to conclude
that the critical activity of DBD* required the novel C- terminal
portion, but that the slightly longer fragment 4 was the
smallest highly reliable lethal fragment.
The effects of altering single a.a. were consistent with this
conclusion. Table 1 summarizes the single a.a. alterations
made in DBD*, the hypothetical function affected by each if it
were found in the natural hGR, and the extent of death
observed. Eleven mutants caused about the same cell kill as
DBD*. Four mutants showed reduced function, and one of
these, in which the cysteine at position 457 was mutated to
phenylalanine, showed complete loss of lethal responses.
The three others (Y433C, F444P, and E471R) showed
significant but not complete loss of lethality. Eleven mutants
demonstrated increased function, consistently causing
>35% to 50% reductions in cell number; eight of these killed
about half the cells. In six separate transfections, mutants
G439E and Q475P caused cell kill comparable to or greater
than DBD* at 24 hours, but had little effect thereafter,
suggesting that these mutants had resulted in unstable
products. In nine transfections, the E480P mutant failed to
produce any consistent effect.
The single a.a. mutations provide further evidence that it
is highly unlikely that DBD* acts by virtue of the structure/
functions of the natural DBD. Several mutations produced
changes in DBD* lethality inconsistent with native DBD
structure/ function. Thus, conversion of either cysteine 424
or 441 to glycine enhanced lethal activity of DBD*. Both
these cysteines are highly conserved in the nuclear receptor
family and are involved in the coordinate binding of the zinc
ion in the first zinc finger of the DBD. Cysteine 441
participates in the helix that binds in the major groove of
the DNA that comprises the GRE [17]. Mutation of serine
440, another a.a. located in that helix in the natural GR DBD,
to a helix -breaking proline also led to enhanced lethal
activity. Serine 440 is one of three a.a. in the GR’s ‘‘P box’’
that are required for specific GRE site recognition [17].
Mutation of alanine 458 in the dimerization loop of the native
DBD to aspartic acid caused a strong enhancement of DBD*
activity.
We noticed that the frameshift creating DBD* had
completely removed the C-terminal pair of cysteines
employed in the coordinate binding of zinc in the natural
DBD protein. However, a histidine was found in the exact
position of one of the twomissing cysteines. Because this left
open the possibility of cysteine 457, cysteine 463, and the
new histidine 476 coordinately binding a zinc and, thus,
restoring DBD- like structure to DBD*, we mutated histidine
476 to lysine. This produced no significant change in DBD*
activity, and we think it unlikely that a zinc ion is bound in this
region as it is in DBD.
The structures of the 89 a.a. protein encoded by DBD*
and the 32 a.a. peptide of fragment 4 are unknown. Our
results provide the first molecular genetic studies defining
important a.a. residues for their function. Blast search of
GeneBank proteins indicated that the new C-terminal 21 a.a.
sequence is unique. Because the sequence encoding the
first zinc finger motif of the interfinger region is not altered,
the possibility existed that the substructures of those regions
remain intact in DBD*. From our data, however, it is highly
unlikely that DBD* contains substructures equivalent to DBD.
The first zinc finger motif is not important for its lethality.
Furthermore, the effects of our mutations are not consistent
with the apoptotic potency of DBD* requiring a.a. essential
for the classic gene regulatory functions of DBD. The
sequence of DBD* is shown above with the mutated
positions indicated in bold. The four mutants that exhibited
less cell kill than DBD* appeared at positions 433, 444, 457,
and 471 (down arrows), C457F being the only total loss-of -
function mutant. The 11 increased- function mutants are
shown with up arrows (Scheme 2).
It would appear that the novel C- terminal end is important
for the cell lysis function, with many residues between a.a.
455 and 465 critical for function. Of the three alterations in
the sequence that forms the D loop of wild - type DBD, two
cause an increase in cell kill. Both A458 and L456 are
involved in homodimerization of the normal DBD. The
mutations A458D and L456Q should negatively affect this
property; yet, they enhanced cell kill.
An nnpredict query [18] was used to compare the
predicted secondary structure of DBD* with that of the
29 mutants. The query indicated only unknown structure
between a.a. 398 and 420. The remaining DBD* sequence
was predicted to have the following secondary structure
(E=strand,H=helix, and - =unknownstructure) (Scheme3).
When the mutations we created are considered with
reference to this predicted structure, several interesting
points are seen. First, we noted that most of the 21 novel
C- terminal a.a. are predicted to form a helix. The secondary
structure prediction for the increased function mutant A458D
indicated a potential change, with only unknown structure
predicted at positions 455 and 456. Whereas the single a.a.
455 (H) or 456 (E) could not of themselves alone form either
G PG GQ D A TT Y S
" " " " " " " "" " "
MKPDVSSPPSSSSTATTGPPPKLCLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIAIKFEEKTAQHAAIENVFRLE
398 423 # 439 # 450 # 460 # 480
C P F R
Scheme 2.
420 434 443 455 464 468 486
EEE-- - - - - - - -EEEE-- - - -HHH-HHHH- - - -HE-- - - - - -EEEEHHHHHHHHHHHHHHHHH--
Scheme 3.
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helix or strand, they may be involved in structure and
function. This possibility was reinforced by the loss-of -
function mutant C457F, which predicted additional helix-
strand in the region of a.a. 452 to 456 (differences from
DBD* bolded) (Scheme 4)
Therefore, secondary structure in this region may be
important for the lethal function of DBD*.
When the putative C-terminal helix - forming a.a. of
DBD* are plotted on a helical wheel (Figure 2 ), the helix
starting at position 468 has interesting characteristics. The
first two turns (Figure 2A ) show a high proportion of
charged or polar a.a. and only two hydrophobic a.a.
Mutation of one of these to a polar a.a. (F469Y) enhanced
activity. The alteration E471R ( to + ) reduced activity
whereas changing K472 to E did not alter activity (Table 1).
Thus, two or three negative charges along this single turn
support the lethal function, but two positive charges reduce
lethal activity. The helix predicted for the 10 a.a. beginning
at histidine 476 shows about three turns of possibly
amphipathic nature (Figure 2B ), with four of five residues
on one side polar or charged and five of five on the other,
hydrophobic. The increased function mutation A477S
(hydrophobic to polar ) would strengthen the amphipathic
pattern. Substitution of a proline at either position 475 or
480 produced plasmids that gave highly inconsistent
results, suggesting that their products were unstable.
To ascertain whether the activity of DBD* and its mutants
were altering the metabolism of ICR-27-4 cells in a manner
consistent with apoptosis, we used a colorimetric assay for
the quantification of cell viability, based on the presence in
EEEE - - - - - - - - -EEEE- - - - -HHH-HHHH- - -H -HEE - - - - - -EEEEHHHHHHHHHHHHHHHHHH- - -
Scheme 4.
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Gain ( + ) or





G439E x 0 /  Inconstant, n=6
S440P x x 46%±10%, n=9 ( + )
V443P x 0 /  31%
E450A x  / 0 24%
Y455G x 42%±12%, n=6 ( + )
Y433C x 11% (  ) Protein –DNA
K442I x + / 0 x 29% interaction;
F444P x x 9%±11%, n=21 (  ) Transactivation /
R447I x + / 0 x 26% Transrepression
V423E x 0 /  x 34%
C424G x 37%±1%, n=6 ( + )
S425F x 30%
C441G x 47%±9%, n=6 ( + )
C457F x x 1%±3%, n=12x (  )
I465T x x 44%±1%, n=6 ( + )
L456Q x 47%±6%, n=6 ( + )
A458D x 0 /  52%±7%, n=21 ( + )
R460W x + /0 30% Receptor dimerization
D462A x  / 0 38% ( + )
I464T x 51% ( + )
F469Y x 0 / + 47%±3%, n=6 ( + )
E471R  / + 14%±12%, n=12 (  )
K472E + /  23%
Q475P x x Inconstant, n=6 Not present
H476L x + /0 32%
A477S x 48%±1%, n=6 ( + )
E480P x x  / 0 Inconstant, n=9
G451–{ 35%
Q452– { 31%
The 29 mutations of DBD* are given with the new amino acid in the sequence followed by the alteration to the structure and the growth response at 24 to 48 hours
after ICR -27 -4 cells were electroporated with that mutant as well as the potential functional change that might have occurred. Increased - function mutants are
in bold.
yThe percentage reduction in cells electroporated with plasmid expressing the indicated mutant compared to cells electroporated with vector only.
zEach mutant was evaluated by at least three electroporations. Those studied with >3 electroporations are indicated by ±SD and the number of independent
electroporation (n ).
xThe value for C457F represents 1% above control.
{Deletions.
#Refs. [ 16,17 ].
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viable cells of mitochondrial dehydrogenases that reduce the
tetrazolium salt WST-1. By this method, DBD* diminished
the viability of the treated population of ICR-27-4 cells by
24±10% compared to control cells transfected with the
plasmid pHook2, n=10. The 11 increased- function mutants
that killed an average of 45±11% of the treated cells as
evaluated by trypan blue dye exclusion, reduced the viability
of treated cells as assayed by WST-1 by an average of
46±14%, n=22. In Figure 3, the lethal effect of the original
DBD* is shown compared with that of the increased function
mutant A458D and the loss-of - functionmutant C457F, using
the two unrelated methods: direct cell counts of trypan blue
excluding cells and WST-1 formazan formation to evaluate
respiratory function. A similar extent of effect was observed
with both methods. A458D clearly reduced the mitochondrial
function of the ICR-27-4 cells as well as the number of viable
cells compared to the control, to a greater extent than DBD*.
In addition, by either method ICR-27-4 cells transfected with
the mutant C457F showed almost no reduction in cell viability
after 24 to 48 hours of treatment. Similar results were
obtained by the PI dye exclusion method (data not shown).
When evaluated by flow cytometry or PI dye exclusion,
the apoptotic effects of the single a.a. mutants and DBD*
followed the same pattern as with the trypan blue dye
exclusion and WST-1 assays. Figure 4 shows that flow
cytometric forward and side scatter data identify two
populations of cells: the G1 group, PI negative with low side
scatter, represents normal cells, and the G2 group, PI
positive, high side scatter. In Figure 4 the effects of the loss-
of - function mutant F444P (Figure 4C ) are compared to
DBD* (4B) and the control plasmid pHook2 (Figure 4A ).
The blue fluorescent Hoechst 33258 dye stains the
condensed chromatin of apoptotic cells in a characteristic
manner. Figure 5 shows identical fields of cells transfected
with control plasmid, DBD*, and two of its mutants, com-
paring their appearance by phase contrast with their blue
fluorescence, which appears gray in the figure. Figure 5A
shows control ICR-27-4 cells 24 hours after electroporation
with pHook2 vector alone, (Figure 5B ) DBD* treated cells,
(Figure 5C ) the loss-of - functionmutant C457F treated cells,
and (Figure 5D ) the gain-of - function mutant A458D.
Preliminary experiments had shown that the percent of blue
fluorescent cells shown in Figure 5A was virtually the same
with or without vector DNA added. Thus, the obviously
damaged cells are due to the effects of electroporation per se.
However, note the larger number of viable cells in the ICR-
Figure 2. Helical wheel plots of the sequence from a.a. 468 through 485 of
DBD*. For purposes of clarity, a.a. 468 to 474 (A ) and 476 to 485 (B ) are
plotted separately. Mutated a.a. are indicated by the arrows, with the new a.a.
at the arrow tip.
Figure 3. Apoptotic activity of DBD* compared with two of its single a.a.
mutants. Cell viability was evaluated by trypan blue dye exclusion ( open
bars ), and mitochondrial function by WST -1 (black bars ). ICR -27 -4 cells
were electroporated with the indicated GR fragment in pHook2 plasmid and
the growth response was compared to control cells electroporated with
pHook2 plasmid alone. The response of cells at 24 and 48 hours was
averaged and expressed as percent reduction compared to control cells;
n=10 for DBD*, 6 for A458D, and 5 for C457F. **Indicates significant
difference from DBD*, P< .01.
Figure 4. Comparison of lethality of DBD* and loss - of - function mutant
F444P. Twenty - four hours after electroporation with various pHook2
plasmids, cells were evaluated for PI staining and light scattering by flow
cytometry. The threshold was set to gate out cell debris and aggregates. Only
the singlet cell population was analyzed; 10,000 to 20,000 events were
accumulated. G1 represents viable cells; G2 represents the population of cells
undergoing apoptosis. (A ) Electroporation with pHook2, (B ) with pHook2 /
DBD*, (C ) with the loss - of - function mutant pHook2 /F444P. (D ) shows the
ratios of cells in the dead (G2 ) / viable (G1 ) populations after each treatment.
The G2 /G1 ratio for DBD* (B ) is significantly higher than pHook2 vector (A )
or the mutant F444P (C ); n=5. **Indicates significant difference of DBD* from
(A ), P= .002 or (C ), P= .007.
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27-4 cultures treated with pHook2 vector alone or in those
treated with the loss-of - function mutant C457F, compared
with cells given DBD* or A458D. Among the surviving cells,
DBD* and the increased- function mutant A458D also had
caused a large increase in the percent of Hoechst-
fluorescent positive nuclei. Thus, by the use of several
methods, we demonstrate that treatment of steroid- resistant
ICR-27-4 cells with DBD* or certain mutant fragments
thereof causes changes consistent with apoptotic cell death.
Conclusions
These results conclusively show that transfection with DBD*
alone is capable of killing the GR receptor–deficient cell
clone ICR-27-4 by apoptotic processes. A smaller gene
fragment of DBD*, encoding its C- terminal 32 a.a., is even
more potent and suggests that this is the minimal fragment
that reliably produces maximum cell kill. These results now
provide the base for detailed structural and mutational
analyses of this minimal fragment. Together with our
previous survey [3], these results suggest that DBD* or the
subfragment would be effective against malignant lymphoid
cells in general. Mutations of single a.a. in DBD* can result in
increases or decreases of lethal activity, which strongly
suggests that 28 and 38 structure of its product are important
for function. The effects of these mutations as well as other
published studies are inconsistent with DBD* — or more
specifically pDBD*, its protein product — having a structure
like that of the original hGR DBD from which it was derived.
The mutations show that most of the lethal activity requires
the C-terminal1/3 of the DBD*, and that the unique 21 a.a.
C- terminal sequence is critically important. However, alone
the 21 a.a. coding sequence is less effective.
The nature of the predicted C-terminal protein helix in
DBD* suggests a potential for protein–protein interactions.
We hypothesize that specific intermolecular interactions
cause DBD* to block cellular functions critical for continued
vitality, thereby activating apoptosis. A search for these
putative sites of cell - type–specific interactions could prove
therapeutically fruitful and are currently underway in our
laboratory.
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Figure 5. Microscopic appearance of ICR -27 -4 cells electroporated with
pHook2 plasmids. Cultures containing equal numbers of cells were trans-
fected, plated, and examined 24 hours later. Each pair of panels shows one
microscopic field of cells, typical of the culture as a whole, in phase contrast
( left ) and fluorescence ( right ) after transfection of ICR -27 -4 cells with
pHook2 vector (A ), pHook2 /DBD* (B ), the loss - of - function mutant C457
(C ), and the increased function mutant A458D (D ). Original magnification,
400.
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